Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
18F-FGD-PET measures predict mRCC TKI response

18F-FGD-PET measures predict mRCC TKI response

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Multiple lines of targeted therapy extend life for mRCC patients

Multiple lines of targeted therapy extend life for mRCC patients

Adoptive T-cell therapy may help in treating liver cancer, says study

Adoptive T-cell therapy may help in treating liver cancer, says study

Researchers identify experimental drugs to block treatment-resistant leukemia

Researchers identify experimental drugs to block treatment-resistant leukemia

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Hopkins scientists design new mouse that mimics common form of leukemia

Hopkins scientists design new mouse that mimics common form of leukemia

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

New drug combination therapy effectively kills cancer cells

New drug combination therapy effectively kills cancer cells

Discoveries pave way for use of new therapies for advanced thyroid cancer

Discoveries pave way for use of new therapies for advanced thyroid cancer

Antioxidant substances in red wine, dark chocolate, olive oil linked with health benefits

Antioxidant substances in red wine, dark chocolate, olive oil linked with health benefits

FDA grants Priority Review designation to sNDA for Nexavar tablets

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Study provides important details for recently identified target in lung adenocarcinoma

Study provides important details for recently identified target in lung adenocarcinoma

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma